Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

Theonie Anastassiadis, Sean Deacon, Karthik Devarajan et al. · Nature Biotechnology · 2011 · 909 citations · Full text

Drug Target, Signal Transduction, Signaling Pathway +10

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner et al. · Cancer Research · 2010 · 501 citations

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien et al. · Journal of Medicinal Chemistry · 2010 · 295 citations · Full text

The selectivity of inhibitors of protein kinase CK2: an update

Mario A. Pagano, Jenny Bain, Zygmunt Kazimierczuk et al. · Biochemical Journal · 2008 · 240 citations · Full text

Chemoprevention Strategy, Protein Kinase Ck2, Pathology +21

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

Kyu-Tae Kim, Kristin Baird, Joon-Young Ahn et al. · Blood · 2004 · 228 citations